Global Immunotherapy Drugs Market – Global Industry Analysis and Forecast (2017-2024) _ by Type of Drug, by Therapy Area, by End-User, and by Geography.

Global Immunotherapy Drugs Market – Global Industry Analysis and Forecast (2017-2024) _ by Type of Drug, by Therapy Area, by End-User, and by Geography.

Market Scenario

Global Immunotherapy Drugs Market was valued US$ 110.5 Mn in 2016 and  expected to reach US$ 304.96 Mn by 2024 at CAGR of 13.53% (Detailed analysis of the market CAGR is provided in the report). Global Immunotherapy Drugs Market Global Immunotherapy Drugs Market is segmented by type of drug, therapy area, end user, and geography. Type of drug segment is sub segmented as monoclonal antibodies, adult vaccines, checkpoint inhibitors, interferons alpha & beta, interleukins and other drugs. Therapy area segment is classified as cancer, autoimmune and inflammatory diseases, infectious diseases and other therapy areas. Cancer sub segment is expected to dominate the market growth during forecast period, owing to increasing preference for immunotherapy as a first line of treatment in cancer leading to growing demand for immunotherapy drugs. End user segment is divided as Hospitals, Clinics and Other End Users. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Immunotherapy Drugs are used to improve human immunity system to fight against infectious diseases and cancer as well as to enhance the overall immunity of the body and restricts the growth of the cancer cells. In this treatment, immune cells kill the cancer cells from the body. High prevalence rate of lifestyle diseases and increasing demand for MABS are trending the overall Global Immunotherapy Drugs Market. However, high cost of immunotherapy treatment will restrain the market growth. North America is expected to dominate the Immunotherapy Drugs Market in forecast period followed by Europe and APAC. Technologically advanced research platforms existence and early adoption of highly developed technologies and a supportive economic structure in this region will fuel the Immunotherapy Drugs Market in North America region. key players operated in the market includes DC Therapeutics, Acorda Therapeutics, Ablynx, AB Science, ELI Lilly and Company, Bristol-Myers Squibb, Astrazeneca, Abbvie, Amgen Inc, Glaxosmithkline PLC, Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.), Novartis International AG, Merck & Co., Inc., F. Hoffmann-La Roche AG

Scope of Global Immunotherapy Drugs Market :

Global Immunotherapy Drugs Market, By Type of Drug: • Monoclonal Antibodies • Adult Vaccines • Preventive Vaccines • Therapeutic Vaccines • Checkpoint Inhibitors • Interferons Alpha & Beta • Interleukins • Other Drugs Global Immunotherapy Drugs Market, By Therapy Area: • Cancer • Autoimmune and Inflammatory Diseases • Infectious Diseases • Other Therapy Areas Global Immunotherapy Drugs Market, By End-User: • Hospitals • Clinics • Other End Users Global Immunotherapy Drugs Market, By Geography: • North America • Europe • Asia Pacific • Middle East & Africa • Latin America Key Players in the Global Immunotherapy Drugs Market Are: • DC Therapeutics • Acorda Therapeutics • Ablynx • AB Science • ELI Lilly and Company • Bristol-Myers Squibb • Astrazeneca • Abbvie • Amgen Inc • Glaxosmithkline PLC • Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.) • Novartis International AG • Merck & Co., Inc. • F. Hoffmann-La Roche AG   Available Customization: Maximize Market Research offers customization of report and scope of the report as per the specific requirement of our client.   Global Drug Discovery Services Market : Global Industry Analysis and Forecast 2024

Table of Contents

Global Immunotherapy Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 1.4. Key Questions Answered 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations Used 2.3. Research Methodology 3. Executive Summary 3.1. Global Immunotherapy Drugs Market Size, by Market Value (US$ Mn) and Market, by Region 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.3. Drivers and Restraints Snapshot Analysis 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.3.4. Porter’s Analysis 4.3.5. Value Chain Analysis 4.3.6. SWOT Analysis 5. Global Immunotherapy Drugs Market Analysis and Forecast 5.1. Global Immunotherapy Drugs Market Analysis and Forecast 5.2. Global Immunotherapy Drugs Market Size& Y-o-Y Growth Analysis 5.2.1. North America 5.2.2. Europe 5.2.3. Asia Pacific 5.2.4. Middle East & Africa 5.2.5. Latin America 6. Global Immunotherapy Drugs Market Analysis and Forecast, by End-user 6.1. Introduction and Definition 6.2. Key Findings 6.3. Global Immunotherapy Drugs Market Value Share Analysis, by End-user 6.4. Market Size (US$ Mn) Forecast, by End-user 6.5. Global Immunotherapy Drugs Market Analysis, by End-user 6.6. Immunotherapy Drugs Market Attractiveness Analysis, by End-user 7. Global Immunotherapy Drugs Market Analysis and Forecast, by Type of Drug 7.1. Introduction and Definition 7.2. Global Immunotherapy Drugs Market Value Share Analysis, by Type of Drug 7.3. Market Size (US$ Mn) Forecast, by Type of Drug 7.4. Global Immunotherapy Drugs Market Analysis, by Type of Drug 7.5. Global Immunotherapy Drugs Market Attractiveness Analysis, by Type of Drug 8. Global Immunotherapy Drugs Market Analysis and Forecast, Therapy Area 8.1. Introduction and Definition 8.2. Global Immunotherapy Drugs Market Value Share Analysis, Therapy Area 8.3. Market Size (US$ Mn) Forecast, Therapy Area 8.4. Global Immunotherapy Drugs Market Analysis, Therapy Area 8.5. Global Immunotherapy Drugs Market Attractiveness Analysis, Therapy Area 9. Global Immunotherapy Drugs Market Analysis, by Region 9.1. Global Immunotherapy Drugs Market Value Share Analysis, by Region 9.2. Market Size (US$ Mn) Forecast, by Region 9.3. Global Immunotherapy Drugs Market Attractiveness Analysis, by Region 10. North America Immunotherapy Drugs Market Analysis 10.1. Key Findings 10.2. North America Immunotherapy Drugs Market Overview 10.3. North America Immunotherapy Drugs Market Value Share Analysis, by End-user 10.4. North America Immunotherapy Drugs Market Forecast, by End-user 10.4.1. Hospitals 10.4.2. Clinics 10.4.3. Other End Users 10.5. North America Immunotherapy Drugs Market Value Share Analysis, by Type of Drug 10.6. North America Immunotherapy Drugs Market Forecast, by Type of Drug 10.6.1. Monoclonal Antibodies 10.6.2. Adult Vaccines 10.6.3. Preventive Vaccines 10.6.4. Therapeutic Vaccines 10.6.5. Checkpoint Inhibitors 10.6.6. Interferons Alpha & Beta 10.6.7. Interleukins 10.6.8. Other Drugs 10.7. North America Immunotherapy Drugs Market Value Share Analysis, Therapy Area 10.8. North America Immunotherapy Drugs Market Forecast, Therapy Area 10.8.1. Cancer 10.8.2. Autoimmune and Inflammatory Diseases 10.8.3. Infectious Diseases 10.8.4. Other Therapy Areas 10.9. North America Immunotherapy Drugs Market Value Share Analysis, by Country 10.10. North America Immunotherapy Drugs Market Forecast, by Country 10.10.1.1. U.S., 2018–2026 10.10.1.2. Canada, 2018–2026 10.11. North America Immunotherapy Drugs Market Analysis, by Country 10.12. U.S. Immunotherapy Drugs Market Forecast, by End-user 10.12.1. Hospitals 10.12.2. Clinics 10.12.3. Other End Users 10.13. U.S. Immunotherapy Drugs Market Forecast, by Type of Drug 10.13.1. Monoclonal Antibodies 10.13.2. Adult Vaccines 10.13.3. Preventive Vaccines 10.13.4. Therapeutic Vaccines 10.13.5. Checkpoint Inhibitors 10.13.6. Interferons Alpha & Beta 10.13.7. Interleukins 10.13.8. Other Drugs 10.14. U.S. Immunotherapy Drugs Market Forecast, Therapy Area 10.14.1. Cancer 10.14.2. Autoimmune and Inflammatory Diseases 10.14.3. Infectious Diseases 10.14.4. Other Therapy Areas 10.15. Canada Immunotherapy Drugs Market Forecast, by End-user 10.15.1. Hospitals 10.15.2. Clinics 10.15.3. Other End Users 10.16. Canada Immunotherapy Drugs Market Forecast, by Type of Drug 10.16.1. Monoclonal Antibodies 10.16.2. Adult Vaccines 10.16.3. Preventive Vaccines 10.16.4. Therapeutic Vaccines 10.16.5. Checkpoint Inhibitors 10.16.6. Interferons Alpha & Beta 10.16.7. Interleukins 10.16.8. Other Drugs 10.17. Canada Immunotherapy Drugs Market Forecast, Therapy Area 10.17.1. Cancer 10.17.2. Autoimmune and Inflammatory Diseases 10.17.3. Infectious Diseases 10.17.4. Other Therapy Areas 10.18. North America Immunotherapy Drugs Market Attractiveness Analysis 10.18.1. By End-user 10.18.2. By Type of Drug 10.18.3. Therapy Area 10.19. PEST Analysis 11. Europe Immunotherapy Drugs Market Analysis 11.1. Key Findings 11.2. Europe Immunotherapy Drugs Market Overview 11.3. Europe Immunotherapy Drugs Market Value Share Analysis, by End-user 11.4. Europe Immunotherapy Drugs Market Forecast, by End-user 11.4.1. Hospitals 11.4.2. Clinics 11.4.3. Other End Users 11.5. Europe Immunotherapy Drugs Market Value Share Analysis, by Type of Drug 11.6. Europe Immunotherapy Drugs Market Forecast, by Type of Drug 11.6.1. Monoclonal Antibodies 11.6.2. Adult Vaccines 11.6.3. Preventive Vaccines 11.6.4. Therapeutic Vaccines 11.6.5. Checkpoint Inhibitors 11.6.6. Interferons Alpha & Beta 11.6.7. Interleukins 11.6.8. Other Drugs 11.7. Europe Immunotherapy Drugs Market Value Share Analysis, Therapy Area 11.8. Europe Immunotherapy Drugs Market Forecast, Therapy Area 11.8.1. Cancer 11.8.2. Autoimmune and Inflammatory Diseases 11.8.3. Infectious Diseases 11.8.4. Other Therapy Areas 11.9. Europe Immunotherapy Drugs Market Value Share Analysis, by Country 11.10. Europe Immunotherapy Drugs Market Forecast, by Country 11.10.1.1. Germany 11.10.1.2. U.K. 11.10.1.3. France 11.10.1.4. Italy 11.10.1.5. Spain 11.10.1.6. Rest of Europe 11.11. Europe Immunotherapy Drugs Market Analysis, by Country/ Sub-region 11.12. Germany Immunotherapy Drugs Market Forecast, by End-user 11.12.1. Hospitals 11.12.2. Clinics 11.12.3. Other End Users 11.13. Germany Immunotherapy Drugs Market Forecast, by Type of Drug 11.13.1. Monoclonal Antibodies 11.13.2. Adult Vaccines 11.13.3. Preventive Vaccines 11.13.4. Therapeutic Vaccines 11.13.5. Checkpoint Inhibitors 11.13.6. Interferons Alpha & Beta 11.13.7. Interleukins 11.13.8. Other Drugs 11.14. Germany Immunotherapy Drugs Market Forecast, Therapy Area 11.14.1. Cancer 11.14.2. Autoimmune and Inflammatory Diseases 11.14.3. Infectious Diseases 11.14.4. Other Therapy Areas 11.15. U.K. Immunotherapy Drugs Market Forecast, by End-user 11.15.1. Hospitals 11.15.2. Clinics 11.15.3. Other End Users 11.16. U.K. Immunotherapy Drugs Market Forecast, by Type of Drug 11.16.1. Monoclonal Antibodies 11.16.2. Adult Vaccines 11.16.3. Preventive Vaccines 11.16.4. Therapeutic Vaccines 11.16.5. Checkpoint Inhibitors 11.16.6. Interferons Alpha & Beta 11.16.7. Interleukins 11.16.8. Other Drugs 11.17. U.K. Immunotherapy Drugs Market Forecast, Therapy Area 11.17.1. Cancer 11.17.2. Autoimmune and Inflammatory Diseases 11.17.3. Infectious Diseases 11.17.4. Other Therapy Areas 11.18. France Immunotherapy Drugs Market Forecast, by End-user 11.18.1. Hospitals 11.18.2. Clinics 11.18.3. Other End Users 11.19. France Immunotherapy Drugs Market Forecast, by Type of Drug 11.19.1. Monoclonal Antibodies 11.19.2. Adult Vaccines 11.19.3. Preventive Vaccines 11.19.4. Therapeutic Vaccines 11.19.5. Checkpoint Inhibitors 11.19.6. Interferons Alpha & Beta 11.19.7. Interleukins 11.19.8. Other Drugs 11.20. France Immunotherapy Drugs Market Forecast, Therapy Area 11.20.1. Cancer 11.20.2. Autoimmune and Inflammatory Diseases 11.20.3. Infectious Diseases 11.20.4. Other Therapy Areas 11.21. Italy Immunotherapy Drugs Market Forecast, by End-user 11.21.1. Hospitals 11.21.2. Clinics 11.21.3. Other End Users 11.22. Italy Immunotherapy Drugs Market Forecast, by Type of Drug 11.22.1. Monoclonal Antibodies 11.22.2. Adult Vaccines 11.22.3. Preventive Vaccines 11.22.4. Therapeutic Vaccines 11.22.5. Checkpoint Inhibitors 11.22.6. Interferons Alpha & Beta 11.22.7. Interleukins 11.22.8. Other Drugs 11.23. Italy Immunotherapy Drugs Market Forecast, Therapy Area 11.23.1. Cancer 11.23.2. Autoimmune and Inflammatory Diseases 11.23.3. Infectious Diseases 11.23.4. Other Therapy Areas 11.24. Spain Immunotherapy Drugs Market Forecast, by End-user 11.24.1. Hospitals 11.24.2. Clinics 11.24.3. Other End Users 11.25. Spain Immunotherapy Drugs Market Forecast, by Type of Drug 11.25.1. Monoclonal Antibodies 11.25.2. Adult Vaccines 11.25.3. Preventive Vaccines 11.25.4. Therapeutic Vaccines 11.25.5. Checkpoint Inhibitors 11.25.6. Interferons Alpha & Beta 11.25.7. Interleukins 11.25.8. Other Drugs 11.26. Spain Immunotherapy Drugs Market Forecast, Therapy Area 11.26.1. Cancer 11.26.2. Autoimmune and Inflammatory Diseases 11.26.3. Infectious Diseases 11.26.4. Other Therapy Areas 11.27. Rest of Europe Immunotherapy Drugs Market Forecast, by End-user 11.27.1. Hospitals 11.27.2. Clinics 11.27.3. Other End Users 11.28. Rest of Europe Immunotherapy Drugs Market Forecast, by Type of Drug 11.28.1. Monoclonal Antibodies 11.28.2. Adult Vaccines 11.28.3. Preventive Vaccines 11.28.4. Therapeutic Vaccines 11.28.5. Checkpoint Inhibitors 11.28.6. Interferons Alpha & Beta 11.28.7. Interleukins 11.28.8. Other Drugs 11.29. Rest of Europe Immunotherapy Drugs Market Forecast, Therapy Area 11.29.1. Cancer 11.29.2. Autoimmune and Inflammatory Diseases 11.29.3. Infectious Diseases 11.29.4. Other Therapy Areas 11.30. Europe Immunotherapy Drugs Market Attractiveness Analysis 11.30.1. By End-user 11.30.2. By Type of Drug 11.30.3. Therapy Area 11.31. PEST Analysis 12. Asia Pacific Immunotherapy Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific Immunotherapy Drugs Market Overview 12.3. Asia Pacific Immunotherapy Drugs Market Value Share Analysis, by End-user 12.4. Asia Pacific Immunotherapy Drugs Market Forecast, by End-user 12.4.1. Hospitals 12.4.2. Clinics 12.4.3. Other End Users 12.5. Asia Pacific Immunotherapy Drugs Market Value Share Analysis, by Type of Drug 12.6. Asia Pacific Immunotherapy Drugs Market Forecast, by Type of Drug 12.6.1. Monoclonal Antibodies 12.6.2. Adult Vaccines 12.6.3. Preventive Vaccines 12.6.4. Therapeutic Vaccines 12.6.5. Checkpoint Inhibitors 12.6.6. Interferons Alpha & Beta 12.6.7. Interleukins 12.6.8. Other Drugs 12.7. Asia Pacific Immunotherapy Drugs Market Value Share Analysis, Therapy Area 12.8. Asia Pacific Immunotherapy Drugs Market Forecast, Therapy Area 12.8.1. Cancer 12.8.2. Autoimmune and Inflammatory Diseases 12.8.3. Infectious Diseases 12.8.4. Other Therapy Areas 12.9. Asia Pacific Immunotherapy Drugs Market Value Share Analysis, by Country 12.10. Asia Pacific Immunotherapy Drugs Market Forecast, by Country 12.10.1. China, 2018–2026 12.10.2. India, 2018–2026 12.10.3. Japan, 2018–2026 12.10.4. ASEAN, 2018–2026 12.10.5. Rest of Asia Pacific, 2018–2026 12.11. Asia Pacific Immunotherapy Drugs Market Analysis, by Country/ Sub-region 12.12. China Immunotherapy Drugs Market Forecast, by End-user 12.12.1. Hospitals 12.12.2. Clinics 12.12.3. Other End Users 12.13. China Immunotherapy Drugs Market Forecast, by Type of Drug 12.13.1. Monoclonal Antibodies 12.13.2. Adult Vaccines 12.13.3. Preventive Vaccines 12.13.4. Therapeutic Vaccines 12.13.5. Checkpoint Inhibitors 12.13.6. Interferons Alpha & Beta 12.13.7. Interleukins 12.13.8. Other Drugs 12.14. China Immunotherapy Drugs Market Forecast, Therapy Area 12.14.1. Cancer 12.14.2. Autoimmune and Inflammatory Diseases 12.14.3. Infectious Diseases 12.14.4. Other Therapy Areas 12.15. India Immunotherapy Drugs Market Forecast, by End-user 12.15.1. Hospitals 12.15.2. Clinics 12.15.3. Other End Users 12.16. India Immunotherapy Drugs Market Forecast, by Type of Drug 12.16.1. Monoclonal Antibodies 12.16.2. Adult Vaccines 12.16.3. Preventive Vaccines 12.16.4. Therapeutic Vaccines 12.16.5. Checkpoint Inhibitors 12.16.6. Interferons Alpha & Beta 12.16.7. Interleukins 12.16.8. Other Drugs 12.17. India Immunotherapy Drugs Market Forecast, Therapy Area 12.17.1. Cancer 12.17.2. Autoimmune and Inflammatory Diseases 12.17.3. Infectious Diseases 12.17.4. Other Therapy Areas 12.18. Japan Immunotherapy Drugs Market Forecast, by End-user 12.18.1. Hospitals 12.18.2. Clinics 12.18.3. Other End Users 12.19. Japan Immunotherapy Drugs Market Forecast, by Type of Drug 12.19.1. Monoclonal Antibodies 12.19.2. Adult Vaccines 12.19.3. Preventive Vaccines 12.19.4. Therapeutic Vaccines 12.19.5. Checkpoint Inhibitors 12.19.6. Interferons Alpha & Beta 12.19.7. Interleukins 12.19.8. Other Drugs 12.20. Japan Immunotherapy Drugs Market Forecast, Therapy Area 12.20.1. Cancer 12.20.2. Autoimmune and Inflammatory Diseases 12.20.3. Infectious Diseases 12.20.4. Other Therapy Areas 12.21. ASEAN Immunotherapy Drugs Market Forecast, by End-user 12.21.1. Hospitals 12.21.2. Clinics 12.21.3. Other End Users 12.22. ASEAN Immunotherapy Drugs Market Forecast, by Type of Drug 12.22.1. Monoclonal Antibodies 12.22.2. Adult Vaccines 12.22.3. Preventive Vaccines 12.22.4. Therapeutic Vaccines 12.22.5. Checkpoint Inhibitors 12.22.6. Interferons Alpha & Beta 12.22.7. Interleukins 12.22.8. Other Drugs 12.23. ASEAN Immunotherapy Drugs Market Forecast, Therapy Area 12.23.1. Cancer 12.23.2. Autoimmune and Inflammatory Diseases 12.23.3. Infectious Diseases 12.23.4. Other Therapy Areas 12.24. Rest of Asia Pacific Immunotherapy Drugs Market Forecast, by End-user 12.24.1. Predictive maintenance and machinery inspection 12.24.2. Hospitals 12.24.3. Clinics 12.24.4. Other End Users 12.25. Rest of Asia Pacific Immunotherapy Drugs Market Forecast, by Type of Drug 12.25.1. Monoclonal Antibodies 12.25.2. Adult Vaccines 12.25.3. Preventive Vaccines 12.25.4. Therapeutic Vaccines 12.25.5. Checkpoint Inhibitors 12.25.6. Interferons Alpha & Beta 12.25.7. Interleukins 12.25.8. Other Drugs 12.26. Rest of Asia Pacific Immunotherapy Drugs Market Forecast, Therapy Area 12.26.1. Cancer 12.26.2. Autoimmune and Inflammatory Diseases 12.26.3. Infectious Diseases 12.26.4. Other Therapy Areas 12.27. Asia Pacific Immunotherapy Drugs Market Attractiveness Analysis 12.27.1. By End-user 12.27.2. By Type of Drug 12.27.3. Therapy Area 12.28. PEST Analysis 13. Middle East & Africa Immunotherapy Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Immunotherapy Drugs Market Overview 13.3. Middle East & Africa Immunotherapy Drugs Market Value Share Analysis, by End-user 13.4. Middle East & Africa Immunotherapy Drugs Market Forecast, by End-user 13.4.1. Hospitals 13.4.2. Clinics 13.4.3. Other End Users 13.5. Middle East & Africa Immunotherapy Drugs Market Value Share Analysis, by Type of Drug 13.6. Middle East & Africa Immunotherapy Drugs Market Forecast, by Type of Drug 13.6.1. Monoclonal Antibodies 13.6.2. Adult Vaccines 13.6.3. Preventive Vaccines 13.6.4. Therapeutic Vaccines 13.6.5. Checkpoint Inhibitors 13.6.6. Interferons Alpha & Beta 13.6.7. Interleukins 13.6.8. Other Drugs 13.7. Middle East & Africa Immunotherapy Drugs Market Value Share Analysis, Therapy Area 13.8. Middle East & Africa Immunotherapy Drugs Market Forecast, Therapy Area 13.8.1. Cancer 13.8.2. Autoimmune and Inflammatory Diseases 13.8.3. Infectious Diseases 13.8.4. Other Therapy Areas 13.9. Middle East & Africa Immunotherapy Drugs Market Value Share Analysis, by Country 13.10. Middle East & Africa Immunotherapy Drugs Market Forecast, by Country 13.10.1. GCC, 2018–2026 13.10.2. South Africa, 2018–2026 13.10.3. Rest of Middle East & Africa, 2018–2026 13.11. Middle East & Africa Immunotherapy Drugs Market Analysis, by Country/ Sub-region 13.12. GCC Immunotherapy Drugs Market Forecast, by End-user 13.12.1. Hospitals 13.12.2. Clinics 13.12.3. Other End Users 13.13. GCC Immunotherapy Drugs Market Forecast, by Type of Drug 13.13.1. Monoclonal Antibodies 13.13.2. Adult Vaccines 13.13.3. Preventive Vaccines 13.13.4. Therapeutic Vaccines 13.13.5. Checkpoint Inhibitors 13.13.6. Interferons Alpha & Beta 13.13.7. Interleukins 13.13.8. Other Drugs 13.14. GCC Immunotherapy Drugs Market Forecast, Therapy Area 13.14.1. Cancer 13.14.2. Autoimmune and Inflammatory Diseases 13.14.3. Infectious Diseases 13.14.4. Other Therapy Areas 13.15. South Africa Immunotherapy Drugs Market Forecast, by End-user 13.15.1. Hospitals 13.15.2. Clinics 13.15.3. Other End Users 13.16. South Africa Immunotherapy Drugs Market Forecast, by Type of Drug 13.16.1. Monoclonal Antibodies 13.16.2. Adult Vaccines 13.16.3. Preventive Vaccines 13.16.4. Therapeutic Vaccines 13.16.5. Checkpoint Inhibitors 13.16.6. Interferons Alpha & Beta 13.16.7. Interleukins 13.16.8. Other Drugs 13.17. South Africa Immunotherapy Drugs Market Forecast, Therapy Area 13.17.1. Cancer 13.17.2. Autoimmune and Inflammatory Diseases 13.17.3. Infectious Diseases 13.17.4. Other Therapy Areas 13.18. Rest of Middle East & Africa Immunotherapy Drugs Market Forecast, by End-user 13.18.1. Hospitals 13.18.2. Clinics 13.18.3. Other End Users 13.19. Rest of Middle East & Africa Immunotherapy Drugs Market Forecast, by Type of Drug 13.19.1. Monoclonal Antibodies 13.19.2. Adult Vaccines 13.19.3. Preventive Vaccines 13.19.4. Therapeutic Vaccines 13.19.5. Checkpoint Inhibitors 13.19.6. Interferons Alpha & Beta 13.19.7. Interleukins 13.19.8. Other Drugs 13.20. Rest of Middle East & Africa Immunotherapy Drugs Market Forecast, Therapy Area 13.20.1. Cancer 13.20.2. Autoimmune and Inflammatory Diseases 13.20.3. Infectious Diseases 13.20.4. Other Therapy Areas 13.21. Middle East & Africa Immunotherapy Drugs Market Attractiveness Analysis 13.21.1. By End-user 13.21.2. By Type of Drug 13.21.3. Therapy Area 13.22. PEST Analysis 14. Latin America Immunotherapy Drugs Market Analysis 14.1. Key Findings 14.2. Latin America Immunotherapy Drugs Market Overview 14.3. Latin America Immunotherapy Drugs Market Value Share Analysis, by End-user 14.4. Latin America Immunotherapy Drugs Market Forecast, by End-user 14.4.1. Hospitals 14.4.2. Clinics 14.4.3. Other End Users 14.5. Latin America Immunotherapy Drugs Market Value Share Analysis, by Type of Drug 14.6. Latin America Immunotherapy Drugs Market Forecast, by Type of Drug 14.6.1. Monoclonal Antibodies 14.6.2. Adult Vaccines 14.6.3. Preventive Vaccines 14.6.4. Therapeutic Vaccines 14.6.5. Checkpoint Inhibitors 14.6.6. Interferons Alpha & Beta 14.6.7. Interleukins 14.6.8. Other Drugs 14.7. Latin America Immunotherapy Drugs Market Value Share Analysis, Therapy Area 14.8. Latin America Immunotherapy Drugs Market Forecast, Therapy Area 14.8.1. Cancer 14.8.2. Autoimmune and Inflammatory Diseases 14.8.3. Infectious Diseases 14.8.4. Other Therapy Areas 14.9. Latin America Immunotherapy Drugs Market Value Share Analysis, by Country 14.10. Latin America Immunotherapy Drugs Market Forecast, by Country 14.10.1.1. Brazil, 2018–2026 14.10.1.2. Mexico, 2018–2026 14.10.1.3. Rest of Latin America, 2018–2026 14.11. Latin America Immunotherapy Drugs Market Analysis, by Country/ Sub-region 14.12. Brazil Immunotherapy Drugs Market Forecast, by End-user 14.12.1. Hospitals 14.12.2. Clinics 14.12.3. Other End Users 14.13. Brazil Immunotherapy Drugs Market Forecast, by Type of Drug 14.13.1. Monoclonal Antibodies 14.13.2. Adult Vaccines 14.13.3. Preventive Vaccines 14.13.4. Therapeutic Vaccines 14.13.5. Checkpoint Inhibitors 14.13.6. Interferons Alpha & Beta 14.13.7. Interleukins 14.13.8. Other Drugs 14.14. Brazil Immunotherapy Drugs Market Forecast, Therapy Area 14.14.1. Cancer 14.14.2. Autoimmune and Inflammatory Diseases 14.14.3. Infectious Diseases 14.14.4. Other Therapy Areas 14.15. Mexico Immunotherapy Drugs Market Forecast, by End-user 14.15.1. Hospitals 14.15.2. Clinics 14.15.3. Other End Users 14.16. Mexico Immunotherapy Drugs Market Forecast, by Type of Drug 14.16.1. Monoclonal Antibodies 14.16.2. Adult Vaccines 14.16.3. Preventive Vaccines 14.16.4. Therapeutic Vaccines 14.16.5. Checkpoint Inhibitors 14.16.6. Interferons Alpha & Beta 14.16.7. Interleukins 14.16.8. Other Drugs 14.17. Mexico Immunotherapy Drugs Market Forecast, Therapy Area 14.17.1. Cancer 14.17.2. Autoimmune and Inflammatory Diseases 14.17.3. Infectious Diseases 14.17.4. Other Therapy Areas 14.18. Rest of Latin America Immunotherapy Drugs Market Forecast, by End-user 14.18.1. Hospitals 14.18.2. Clinics 14.18.3. Other End Users 14.19. Rest of Latin America Immunotherapy Drugs Market Forecast, by Type of Drug 14.19.1. Monoclonal Antibodies 14.19.2. Adult Vaccines 14.19.3. Preventive Vaccines 14.19.4. Therapeutic Vaccines 14.19.5. Checkpoint Inhibitors 14.19.6. Interferons Alpha & Beta 14.19.7. Interleukins 14.19.8. Other Drugs 14.20. Rest of Latin America Immunotherapy Drugs Market Forecast, Therapy Area 14.20.1. Cancer 14.20.2. Autoimmune and Inflammatory Diseases 14.20.3. Infectious Diseases 14.20.4. Other Therapy Areas 14.21. Latin America Immunotherapy Drugs Market Attractiveness Analysis 14.21.1. By End-user 14.21.2. By Type of Drug 14.21.3. Therapy Area 14.22. PEST Analysis 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.3. Company Profiles: Key Players 15.3.1. DC Therapeutics 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Business Strategy 15.3.1.4. Recent Developments 15.3.1.5. Manufacturing Footprint 15.3.2. Acorda Therapeutics 15.3.3. Ablynx 15.3.4. AB Science 15.3.5. ELI Lilly and Company 15.3.6. Bristol-Myers Squibb 15.3.7. Astrazeneca 15.3.8. Abbvie 15.3.9. Amgen Inc 15.3.10. Glaxosmithkline PLC 15.3.11. Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.) 15.3.12. Novartis International AG 15.3.13. Merck & Co., Inc. 15.3.14. F. Hoffmann-La Roche AG 16. Primary Key Insights

Inquiry Before Buying

Request Sample

About This Report

Report ID6859
Category Healthcare
Publisher Name
No of Pages
Total Views
Published Date
Contact Us
Call Now